Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

1 (Currently amended). A capsule [[having]] comprising a shell, [[the wall of]] having an outer surface and an opposed inner surface, the inner surface defining at least in part a confined space for holding a drug substance, and the outer surface being exposed to a gastro-intestinal environment, the shell being composed of [[a]] an extruded material comprising a pharmaceutical composition comprising a copolymer of methyl acrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1 [[(Eudragit 4135F®)]] present in an amount of about 20 to 90% w/w; a lubricant present in an amount of 0 to about 30% w/w; a dissolution modifying excipient present in an amount of about 2.5 to about 70% w/w, and optionally a surfactant present in an amount of 0 to 10%, a plasticizer present in the amount of 0 to 10% w/w and/or a processing agent present in an amount of 0 to about 10% w/w, wherein the shell material between and including the inner and outer surfaces is composed of the extruded material.

2. (Previously presented) The capsule shell composition according to Claim 1 wherein the copolymer is present in an amount of about 50 to 90% w/w.

3. (Previously presented) The capsule shell composition according to Claim 1 which comprises a surfactant which is present in an amount of less than 5% w/w.

4. (Previously presented) The capsule shell composition according to Claim 3 wherein the surfactant is sodium dodecyl sulphate or is a block copolymer of ethylene oxide and propylene oxide.

5. (Previously presented) The capsule shell composition according to Claim 4 wherein the surfactant is sodium dodecyl sulphate is present in an amount of less than 2% w/w.

6. (Previously presented) The capsule shell composition according to Claim 4 wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide.

7. (Previously presented) The capsule shell composition according to Claim 1 wherein the lubricant is present in an amount of about 10 to 30% w/w.

8. (Previously presented) The capsule shell composition according to Claim 1 wherein the lubricant is stearyl alcohol, glycerol monostearate (GMS), talc, magnesium stearate, silicon dioxide, amorphous silicic acid, or fumed silica; and combinations or mixtures thereof.

9. (Previously presented) The capsule shell composition according to Claim 8 wherein the lubricant is stearyl alcohol.

10. (Previously presented) The capsule shell composition according to Claim 9 wherein the stearyl alcohol is present from about 10 to about 15% w/w.

11. (Previously presented) The capsule shell composition according to Claim 1 wherein the dissolution modifying excipient is a swellable solid which is ethyl cellulose, cellulose acetate phthalate; hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, or other hydroxyalkylcellulose derivative; and combinations or mixtures thereof.

12. (Previously presented) The capsule shell composition according to Claim 11 wherein the dissolution modifying excipient is hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, or hydroxypropyl cellulose.

13. (Previously presented) The capsule shell composition according to Claim 12 wherein the swellable solid is present in an amount of about 10 to 50% w/w.

14. (Previously presented) The capsule shell composition according to Claim 1 wherein the dissolution modifying excipient is xylitol, mannitol, lactose, pregelatinized starch sodium chloride, sodium starch glycollate, croscarmellose sodium, crospovidone (cross-linked polyvinyl pyrrolidone), copovidone , polyvinyl pyrrolidone, and combinations or mixtures thereof.

15. (Previously presented) The capsule shell composition according to Claim 14 wherein the dissolution modifying excipient is present in an amount of about 40 to 70% w/w.

16. (Previously presented) The capsule shell composition according to Claim 11 wherein the dissolution modifying excipient is a combination of a swellable solid and lactose, sodium starch glycollate, croscarmellose sodium, copovidone, crospovidone (cross-linked polyvinyl pyrrolidone), or polyvinyl pyrrolidone.

17. (Previously presented) The capsule shell composition according to Claim 16 wherein the dissolution modifying excipient is hydroxypropylcellulose and lactose.

18. (Previously presented) The capsule shell composition according to Claim 1 wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide, lecithin, sodium dioctyl sulfosuccinate, sodium dodecyl sulphate, Polyoxyl 40 hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, the sorbitan fatty acid esters, polyethylene glycol, Vitamin E-TPGS® (d-alpha-tocopheryl polyethylene glycol 1000 succinate), sucrose fatty acid ester; and combinations and mixtures thereof.

19. (Previously presented) The capsule shell composition according Claim 18 wherein the dissolution modifying excipient is a combination of a swellable solid and lactose, sodium starch glycollate, croscarmellose sodium, copovidone, crospovidone (cross-linked polyvinyl pyrrolidone), or polyvinyl pyrrolidone.

20. (Previously presented) The capsule shell composition according to Claim 1 wherein the plasticizer is triethyl citrate (TEC), tributyl citrate, acetyl triethyl citrate (ATEC), acetyl tributyl citrate (ATBC), dibutyl phthalate, dibutyl sebacate (DBS), diethyl phthalate, vinyl pyrrolidone glycol triacetate, polyethylene glycol, polyoxyethylene sorbitan monolaurate, propylene glycol, or castor oil; and combinations or mixtures thereof.

21. (Previously presented) The capsule shell composition according to Claim 1 wherein the processing agent is talc.

22. (Previously presented) The capsule shell composition according to Claim 21 wherein the processing agent is present in an amount of about 1 to about 5 % w/w.

23. (Previously presented) The capsule shell composition according to Claim 1 which further comprises an absorption enhancer.

24. (Previously presented) The capsule shell composition according to Claim 23 wherein the absorption enhancer is chitosan, lecithin, lectin, a sucrose fatty acid ester, Vitamin E-TPGS; and combinations or mixtures thereof.

25. (Previously presented) The capsule shell composition according to Claim 1 wherein the copolymer is present in an amount of about 50 to 90% w/w, the lubricant is stearyl alcohol present in an amount of about 10 to about 15% w/w , and the dissolution modifying excipient is hydroxypropylmethylcellulose, hydroxypropylcellulose, or a hydroxylalkyl cellulose derivative or salt thereof.

26. (Previously presented) The capsule shell composition according to Claim 25 wherein the dissolution modifying excipient also includes a disintegrant.

27. (Previously presented) The capsule shell composition according to Claim 26 wherein the disintegrant is sodium starch glycollate, croscarmellose sodium, copovidone, crospovidone

(cross-linked polyvinyl pyrrolidone), or polyvinyl pyrrolidone, or a combination or mixture thereof.

28. (Previously presented) The capsule shell composition according to Claim 25 wherein the dissolution modifying excipient also includes a wicking agent.

29. (Previously presented) The capsule shell composition according to Claim 28 wherein the wicking agent is lactose.

30. (Previously presented) The capsule shell composition according to Claim 25 wherein the processing aid is talc.

31. (Currently amended) The capsule shell ~~pharmaceutical~~ composition according to Claim 1 which is:

	Formulation	% w/w
	Copolymer	75.0
	Stearyl alcohol	5.0
	Croscarmellose sodium	20.0
	Copolymer	75.0
	Stearyl alcohol	5.0
	Sodium starch glycollate	20.0
	Copolymer	85.0
	Stearyl alcohol	5.0
	Xylitol	10.0
	Copolymer	75.0
	Stearyl alcohol	5.0
	Croscarmellose sodium	10.0
	Xylitol	10.0
	Copolymer	75.0

	Formulation	% w/w
	Stearyl alcohol	5.0
	Mannitol	10.0
	Sodium starch glycollate	10.0
	Copolymer	65.0
	Stearyl alcohol	5.0
	Mannitol	10.0
	Sodium starch glycollate	20.0
	Copolymer	80.0
	Stearyl alcohol	5.0
	Sodium starch glycollate	10.0
	Lactose monohydrate	5.0
	Copolymer	75.0
	Stearyl alcohol	5.0
	Sodium starch glycollate	10.0
	Lactose monohydrate	10.0
	Copolymer	85.0
	Stearyl alcohol	5.0
	Lactose monohydrate	10.0
	Copolymer	75.0
	Stearyl alcohol	5.0
	Lactose monohydrate	20.0
	Copolymer	80.0
	Stearyl alcohol	5.0
	Sodium starch glycollate	5.0
	Lactose monohydrate	10.0

	Formulation	% w/w
	Copolymer	70.0
	Stearyl alcohol	5.0

	Formulation	% w/w
	Sodium starch glycollate	5.0
	Lactose monohydrate	20.0
	Copolymer	75.0
	Stearyl alcohol	10.0
	Mannitol	7.5
	Sodium starch glycollate	7.5
	Copolymer	80.0
	Stearyl alcohol	5.0
	Pregelatinized Starch	10.0
	Lactose monohydrate	5.0
	Copolymer	85.0
	Stearyl alcohol	5.0
	Cross linked polyvinyl pyrrolidone	10.0
	Copolymer	80.0
	Stearyl alcohol	5.0
	Sodium starch glycollate	10.0
	Lactose monohydrate	5.0
	Copolymer	75.0
	Stearyl alcohol	10.0
	Sodium starch glycollate	10.0
	Lactose monohydrate	5.0
	Copolymer	85.0
	Stearyl alcohol	5.0
	Sodium chloride	5.0
	Lactose monohydrate	5.0

	Formulation	% w/w
	Copolymer	85.0
	Stearyl alcohol	5.0

	Formulation	% w/w
	Hydroxypropyl cellulose	5.0
	Lactose monohydrate	5.0
	Copolymer	85.0
	Stearyl alcohol	5.0
	Hydroxypropylmethyl cellulose	5.0
	Lactose monohydrate	5.0
	Copolymer	80.0
	Stearyl alcohol	10.0
	Hydroxypropylmethyl cellulose	5.0
	Lactose monohydrate	5.0
	Copolymer	80.0
	Stearyl alcohol	10.0
	Sodium starch glycollate	5.0
	Lactose monohydrate	5.0
	Copolymer	80.0
	Stearyl alcohol	10.0
	Hypromellose phthallate	5.0
	Lactose monohydrate	5.0
	Copolymer	80.0
	Stearyl alcohol	10.0
	Low substituted hydroxypropyl cellulose	5.0
	Lactose monohydrate	5.0
	Copolymer	90.0
	Stearyl alcohol	5.0
	Hydroxypropylmethyl cellulose	5.0

	Formulation	% w/w
	Copolymer	90.0

	Formulation	% w/w
	Stearyl alcohol	5.0
	Lactose monohydrate	5.0
	Copolymer	73.0
	Stearyl alcohol	12.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose monohydrate	5.0
	Copolymer	84.0
	Sodium dodecyl sulphate	1.0
	Croscarmellose sodium	15
	Copolymer	79.0
	Sodium dodecyl sulphate	1.0
	Croscarmellose sodium	10
	Sodium starch glycollate	10
	Copolymer	80.0
	Croscarmellose sodium	10
	Sodium starch glycollate	10
	Copolymer	69.0
	Sodium dodecyl sulphate	1.0
	Croscarmellose sodium	15
	Sodium starch glycollate	15
	Copolymer	79.0
	Polyoxypropylene-polyoxyethylen	1.0
	block copolymer	
	Sodium starch glycollate	20
	Copolymer	79.0
	Polyoxypropylene-polyoxyethylen	1.0
	block copolymer	
	Sodium starch glycollate	20

32. (Currently amended) The ~~A~~ capsule shell ~~pharmaceutical~~ composition ~~comprising~~ according to Claim 1 which is:

Components	# (1) % w/w	(2) w/w	(3) w/w	(4) w/w	(5) w/w	(6) w/w	(7) w/w
Copolymer ~~of methyl acrylate, methyl meth-acrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	45%	35%	25%	15%	75%	65%	55%
Stearyl Alcohol	10%	10%	10%	10%	10%	10%	10%
Lactose	5%	5%	5%	5%	5%	5%	5%
Hydroxypropyl Cellulose	40%	50%	60%	70%	10%	20%	30%
Total	100%	100%	100%	100%	100%	100%	100%

33. (Currently amended) The ~~A~~ capsule shell ~~pharmaceutical~~ composition ~~comprising~~ according to Claim 1 which is::

Components	# (1) % w/w	(2) w/w	(3) w/w	(4) w/w	(5) w/w	(6) w/w
Copolymer ~~of methyl acrylate, methyl meth-acrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	63%	62.9%	62.75%	52%	42%	62%

Croscarmellose sodium	10%	10%	10%	15%	20%	5%
Sodium starch glycollate	10%	10%	10%	15%	20%	5%
Stearyl alcohol	12%	12%	12%	12%	12%	12%
Hydroxypropyl-methylcell	5%	5%	5%	5%	5%	15%
Sodium Dodecyl Sulphate	0%	0.1%	0.25%	1%	1%	1%

34. (Currently amended) The ~~A~~ capsule shell ~~pharmaceutical~~ composition ~~comprising~~ according to Claim 1 which is:

Components	#(1) % w/w	(2) w/w	(3) w/w	(4) w/w	(5) w/w	(6) w/w	(7) w/w
Copolymer ~~of methyl acrylate, methyl meth-acrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	45%	35%	25%	15%	75%	65%	55%
Stearyl Alcohol	10%	10%	10%	10%	10%	10%	10%
Lactose	5%	5%	5%	5%	5%	5%	5%
Hydroxypropyl-cellulos	40%	50%	60%	70%	10%	20%	30%
Total	100%	100%	100%	100%	100%	100%	100%

35. (Currently amended) The ~~A~~ capsule shell ~~pharmaceutical~~ composition ~~comprising~~ according to Claim 1 which is:

Example #	Formulation	%w/w
1	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	73.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose (regular)	5.0
	Glyceryl monostearate	12.0
2	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	53.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose (regular)	5.0
	Hydroxypropylmethyl cellulose phthallate	20.0
	Stearyl alcohol	12.0
~~3~~	~~Copolymer of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	~~20.0~~
	~~Hydroxypropylmethyl cellulose~~	~~10.0~~
	~~Hydroxypropylmethyl cellulose phthallate~~	~~20.0~~
	~~Stearyl alcohol~~	~~12.0~~

~~4~~ 3	Copolymer ~~of methyl acrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	68.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	5.0
	Stearyl alcohol	12.0
~~5~~ 4	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	72.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~6~~ 5	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	71.0
	Hydroxypropylmethyl cellulose	10.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	2.0
	Stearyl alcohol	12.0

~~7~~ 6	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Sodium starch glycollate	20.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~8~~ 7	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	~~62.0—~~75.0
	Sodium starch glycollate	~~20.0~~ 10.0
	Lactose (regular)	~~5.0~~ 10.0
	~~Sodium dodecyl sulphate~~	~~1.0~~
	Stearyl alcohol	~~12.0~~ 5.0
~~9~~ 8	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	72.0
	Sodium starch glycollate	10.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0

~~10~~ 9	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Croscarmellose sodium	20.0
	Lactose (regular)	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~11~~ 10	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Sodium starch glycollate	20.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~12~~ 11	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Hydroxypropylmethyl cellulose phthallate	20.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0

~~13~~ 12	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.5
	Sodium starch glycollate	20.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	0.5
	Stearyl alcohol	12.0
~~14~~ 13	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Croscarmellose sodium	10.0
	Sodium starch glycollate	10.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~15~~ 14	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	67.0
	Croscarmellose sodium	15.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0

~~16~~ 15	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	72.0
	Croscarmellose sodium	10.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~17~~ 16	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	77.0
	Croscarmellose sodium	5.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~18~~ 17	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	52.0
	Croscarmellose sodium	15.0
	Sodium starch glycollate	15.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0

~~19~~ 18	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	42.0
	Croscarmellose sodium	20.0
	Sodium starch glycollate	20.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~20~~ 19	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	42.0
	Croscarmellose sodium	20.0
	Sodium starch glycollate	20.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0
~~21~~ 20	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.0
	Croscarmellose sodium	5.0
	Sodium starch glycollate	5.0
	Hydroxypropylmethyl cellulose	15.0
	Sodium dodecyl sulphate	1.0
	Stearyl alcohol	12.0

~~22~~ 21	Copolymer ~~of methylacrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1~~	62.9
	Croscarmellose sodium	10.0
	Sodium starch glycollate	10.0
	Hydroxypropylmethyl cellulose	5.0
	Sodium dodecyl sulphate	0.1
	Stearyl alcohol	12.0

36. (Cancelled)

37. (Cancelled)

38. (Previously presented) The capsule shell composition according to Claim 1 wherein the lubricant is stearyl alcohol present in an amount of 10 to 15% w/w, the surfactant is SDS or a block copolymer of ethylene oxide and propylene oxide present in an amount less than 5% w/w; and the dissolution modifying excipient is selected from HPC, HPMC, sodium starch glycollate, croscarmellose sodium, copovidone, or lactose, and combinations or mixtures thereof, and is present in an amount of about 2.5 to about 70% w/w.

39. (Previously presented) A capsule shell composition according to Claim 1 that is in the form of an injection molded capsule shell.

40. (Previously presented) A capsule shell composition according to Claim 1 that is in the form of a multicomponent injection molded capsule shell.

41 to 70 (cancelled).

71. (Currently amended) The capsule shell composition according to Claim 1 ~~wherein the pharmaceutical composition~~ which is:

	Dissolution Modifier	Lubricant	Surfactant
1	Hydroxypropylmethylcellulose (5%w/w)	Stearyl alcohol (12%w/w)	None
2	Hydroxypropylmethylcellulose (10%w/w), and HPMCphthalate (20%w/w)	Stearyl alcohol (12%w/w)	None
3	Hydroxypropylmethylcellulose (10%), and Lactose (5%)	Stearyl alcohol (12%)	None
4	Hydroxypropylmethylcellulose (5%)	Stearyl alcohol (12%)	SDS (1%) or Sodium Starch Glycollate (20%) or Tween or a polyoxypropylene-polyoxyethylene block copolymer

72. (Previously presented) The capsule shell composition according to Claim 1 which is

Example #	Formulation	% w/w
1	Copolymer	77.0
	Sodium Dodecyl Sulphate	1.0
	Croscarmellose sodium	5.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
2	Copolymer	68.0
	Croscarmellose sodium	15.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
3	Copolymer	62.0
	Sodium Dodecyl Sulphate	1.0
	Croscarmellose sodium	10.0
	Sodium Starch Glycollate	10.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
4	Copolymer	63.0
	Croscarmellose sodium	10.0
	Sodium Starch Glycollate	10.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
5	Copolymer	52.0
	Sodium Dodecyl Sulphate	1.0
	Croscarmellose sodium	15.0
	Sodium Starch Glycollate	15.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0

6	Copolymer	62.0
	Polyoxypropylene-polyoxyethylene block copolymer	1.0
	Sodium Starch Glycollate	20.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
7	Copolymer	62.0
	polyoxypropylene-polyoxyethylene block copolymer	1.0
	Sodium Starch Glycollate	20.0
	Stearyl Alcohol	12.0
	Hydroxypropylmethyl Cellulose	5.0
8	Copolymer	62.0
	Stearyl Alcohol	12.0
	Croscarmellose sodium	5.0
	Sodium Starch Glycollate	5.0
	Hydroxypropylmethyl Cellulose	15.0
	Sodium Dodecyl Sulphate	1.0
9	Copolymer	42.0
	Stearyl Alcohol	12.0
	Croscarmellose sodium	20.0
	Sodium Starch Glycollate	20.0
	Hydroxypropylmethyl Cellulose	5.0
	Sodium Dodecyl Sulphate	1.0
10	Copolymer	47.0
	Stearyl Alcohol	12.0
	Sodium Starch Glycollate	10.0
	Hydroxypropylmethyl Cellulose	30.0
	Sodium Dodecyl Sulphate	1.0

73. (Currently amended) A solid generally cylindrical linker body having an outer surface, the outer surface being exposed to a gastro-intestinal environment ~~capsule linker~~ the cylindrical linker body being composed of [[a]] an extruded material comprising a pharmaceutical composition comprising a copolymer of methyl acrylate, methyl methacrylate and methacrylic acid with a molar ratio of monomer units represented as 7:3:1 [[(Eudragit 4135F®)]] present in an amount of about 20 to 90% w/w; a lubricant present in an amount of 10 to about 30% w/w; a dissolution modifying excipient present in an amount of about 2.5 to about 70% w/w, and optionally a surfactant present in an amount of less than 5% w/w, a plasticizer present in an amount of 0 to 10% w/w and/or a processing agent present in an amount of 0 to about 10% w/w ~~for moulded capsule, shell or linker components~~ wherein the cylindrical linker body is comprised of the extruded material.

74. (Previously presented) The linker composition according to Claim 73 wherein the copolymer is present in an amount of about 50 to 90% w/w.

75. (Previously presented) The linker composition according to Claim 73 wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide, lecithin, sodium dioctyl sulfosuccinate, sodium dodecyl sulphate, Polyoxyl 40 hydrogenated castor oil, polyoxyethylene sorbitan fatty acid esters, the sorbitan fatty acid esters, polyethylene glycol, Vitamin E-TPGS® (d-alpha-tocopheryl polyethylene glycol 1000 succinate), sucrose fatty acid ester; and combinations and mixtures thereof.

76. (Previously presented) The linker composition according to Claim 75 wherein the surfactant is sodium dodecyl sulphate is present in an amount of less than 2% w/w.

77. (Previously presented) The linker composition according to Claim 75 wherein the surfactant is sodium dodecyl sulphate or is a block copolymer of ethylene oxide and propylene oxide.

78. (Previously presented) The linker composition according to Claim 77 wherein the surfactant is sodium dodecyl sulphate is present in an amount of less than 2% w/w.

79. (Previously presented) The linker composition according to Claim 73 wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide.

80. (Previously presented) The linker composition according to Claim 79 wherein the surfactant is sodium dodecyl sulphate is present in an amount of less than 2% w/w.

81. (Previously presented) The linker composition according to Claim 73 wherein the lubricant is stearyl alcohol, glycerol monostearate (GMS), talc, magnesium stearate, silicon dioxide, amorphous silicic acid, or fumed silica; and combinations or mixtures thereof.

82. (Previously presented) The linker composition according to Claim 81 wherein the lubricant is stearyl alcohol.

83. (Previously presented) The linker composition according to Claim 82 wherein the stearyl alcohol is present from about 10 to about 15% w/w.

84. (Previously presented) The linker composition according to Claim 73 wherein the dissolution modifying excipient is a swellable solid which is ethyl cellulose, cellulose acetate phthalate; hydroxypropyl cellulose, hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, or other hydroxyalkylcellulose derivative; and combinations or mixtures thereof.

85. (Previously presented) The linker composition according to Claim 84 wherein the swellable solid is present in an amount of about 10 to 50% w/w.

86. (Previously presented) The linker composition according to Claim 84 wherein the dissolution modifying excipient is hydroxypropylmethyl cellulose, hydroxypropylmethyl cellulose phthalate, or hydroxypropyl cellulose.

87. (Previously presented) The linker composition according to Claim 86 wherein the swellable solid is present in an amount of 10 to 50% w/w.

88. (Previously presented) The linker composition according to Claim 73 wherein the dissolution modifying excipient is xylitol, mannitol, lactose, pregelatinized starch, sodium chloride, sodium starch glycollate, croscarmellose sodium, crospovidone (cross-linked polyvinyl pyrrolidone), copovidone, polyvinyl pyrrolidone; and combinations or mixtures thereof.

89. (Previously presented) The linker composition according to Claim 88 wherein the dissolution modifying excipient is present in an amount of about 40 to 70% w/w.

90. (Previously presented) The linker composition according to Claim 89 wherein the dissolution modifying excipient is a combination of a swellable solid and lactose, sodium starch glycollate, croscarmellose sodium, copovidone, crospovidone (cross-linked polyvinyl pyrrolidone), or polyvinyl pyrrolidone.

91. (Previously presented) The linker composition according to Claim 90 wherein the dissolution modifying excipient is hydroxypropylcellulose and lactose.

92. (Previously presented) The linker composition according Claim 73 wherein the dissolution modifying excipient is a combination of a swellable solid and lactose, sodium starch glycollate, croscarmellose sodium, copovidone, or crospovidone (cross-linked polyvinyl pyrrolidone).

93. (Previously presented) The linker composition according to Claim 73 wherein the processing agent is talc.

94. (Previously presented) The linker composition according to Claim 93 wherein the processing agent is present in an amount of about 1 to about 5 % w/w.

95. (Previously presented) The linker composition according to Claim 91 wherein the processing agent is talc and is present in an amount of about 1 to about 5 % w/w.

96. (Previously presented) The linker composition according to Claim 73 which further comprises an absorption enhancer.

97. (Previously presented) The linker composition according to Claim 96 wherein the absorption enhancer is chitosan, lecithin, lectin, a sucrose fatty acid ester, Vitamin E-TPGS; and combinations or mixtures thereof.

98 to 111 (Cancelled)

112. (Previously presented) The capsule shell composition according to Claim 1 wherein the wall thickness is in the range of about 0.3 – 0.8 mm.

113. (Previously presented) The capsule shell composition according to Claim 1 wherein the wall thickness is in the range of about 0.3 mm to 0.5 mm.